Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Novo to Introduce Tresiba in Some EU States in First Half

Novo Nordisk A/S, the world’s biggest insulin maker, will start introducing its Tresiba diabetes medicine in Europe during the first half this year.

Novo will make Tresiba available in all European Union countries, Katrine Rud von Sperling, a spokeswoman for the Bagsvaerd, Denmark-based company, said in e-mailed comments.

The “timing of the launch will be dependent on pricing and reimbursement negotiations, with expected first launches during the first half of 2013,” she wrote.

The once-a-day insulin Tresiba, also known as degludec, obtained the European Commission’s marketing authorization on Jan. 21. Novo’s Chief Scientific Officer Mads Krogsgaard Thomsen said in a Nov. 9 interview the company was planning for U.S. approval of the medicine for the first half this year, following the backing of an advisory panel to the Food and Drug Administration.

Novo will give an update on the U.S. regulatory process when it releases full-year results on Jan. 31, Rud von Sperling said.

In Japan, the medicine has been approved and Novo is negotiating a price with the authorities there, she said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.